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Sterile alpha motif (SAM) domain and HD domain-containing protein 1 
(SAMHD1) is a host cell restriction factor that inhibits HIV-1 replication by 
impairing reverse transcription in non-cycling cells such as macrophages, 
dendritic cells and resting CD4+ T cells. SAMHD1 has a dGTP-induced 
dNTPase activity, and therefore was initially proposed to deplete intracellular 
dNTP level below the levels required for reverse transcription of HIV-1. 
However, the phosphorylation of SAMHD1 at position T592 regulates its ability 
to restrict HIV-1 without decreasing cellular dNTP levels, which is not 
consistent with a role for SAMHD1 dNTPase activity in HIV-1 restriction. Here, 
I show that SAMHD1 possesses RNase activity and that the RNase but not the 







characterizing Aicardi-Goutières syndrome (AGS)-associated SAMHD1 
mutations and mutations in the allosteric dGTP-binding site of SAMHD1 for 
defects in RNase or dNTPase activity, I identify SAMHD1 point mutants that 
cause loss of one or both functions. The RNase-positive and dNTPase-
negative SAMHD1D137N mutant is able to restrict HIV-1 infection, whereas the 
RNase-negative and dNTPase-positive SAMHD1Q548A mutant is defective for 
HIV-1 restriction. SAMHD1 associates with HIV-1 RNA and degrades it during 
the early phases of cell infection. SAMHD1 silencing in macrophages and 
CD4+ T cells from healthy donors increases HIV-1 RNA stability, rendering the 
cells permissive for HIV-1 infection. Furthermore, the phosphorylation of 
SAMHD1 at T592 negatively regulates its RNase activity in cells and 
consequently the ability of SAMHD1 to restrict HIV-1 infection. My results 
reveal that the RNase activity of SAMHD1 is responsible for preventing HIV-1 























Human immunodeficiency virus (HIV) — HIV-1 and HIV-2 — causes AIDS and 
belong to a group of retroviruses that are endemic to African apes and Old 
World monkeys and are known as the primate lentiviruses. HIV‑1, which is 
responsible for the global AIDS pandemic, and HIV‑2, which causes AIDS in 
regions of West Africa, are mainly spread by heterosexual transmission and 
replicate in CD4+ T cells and macrophages. HIV infection results in the 
depletion of CD4+ T cells, immunodeficiency and the eventual onset of life-
threatening opportunistic infections.  
HIV enters T cells and macrophages via binding of the viral envelope 
protein gp120 to the coreceptor CD4. The envelope subunit gp41 interacts the 
coreceptor CCR5 or CXCR4 on the target-cell membrane, inducing fusion of 
the viral envelope with the plasma membrane. Once the viral core is released 
into the cytosol, HIV reverse transcriptase (RT) converts RNA into DNA in the 
reverse-transcription complex. That complex matures into the preintegration 
complex, which delivers reverse-transcribed HIV DNA to the nucleus for 
chromosomal integration (Figure 1). Few copies of HIV DNA integrate; thus, 
the bulk of HIV DNA is left behind in the cytosol to be cleared by host enzymes. 
Once the viral genomic DNA is integrated into a host chromosome, viral 







protein Tat. HIV mRNAs are all capped and polyadenylated. The unspliced 
RNA is both translated to generate the Gag and Pol proteins and incorporated 
as genomic RNA into nascent virions at cell-membrane sites where the 
envelope and capsid proteins assemble before budding. 
Mucosal innate immunity is the first line of defense against HIV-1 during 
the early phase of infection, and it also has a crucial role in shaping ensuing 
adaptive immune responses. There are two major types of innate immunity 
involved in HIV-1 infection: cellular and intracellular. Cellular innate immunity 
includes functions of dendritic cells (DCs) that are among the first group of 
cells that contact HIV-1 at the site of infection and that can mediate the trans-
infection of CD4+ T cells (1). The γδ+ T cells play key role in innate responses 
to HIV by generating antiviral factors such as RANTES, MIP-1α and MIP-1β (2). 
Natural killer (NK) cells also serve cellular innate immunity to HIV by 
eliminating infected cells and regulating DC functions (3). Intracellular innate 
immunity includes intrinsic immunity mediated by host factors with important 
roles in restricting HIV-1 replication, such as TRIM5α, APOBEC3G, tetherin 
Figure 1). All of these restriction factors are also encoded by interferon (IFN)-
stimulated genes (ISGs). HIV-1 has evolved effective ways to evade some of 
these restriction factors via accessory proteins, such as Vif to counteract 




































Figure 1. Schematic overview of HIV-1 life cycle and restriction factors of 
HIV-1.  
The classical entry route of HIV-1 in target cells is through attachment at the 
cell surface and fusion. The viral core is delivered in the cytoplasm. After or 
concomitantly with uncoating and nuclear import steps, reverse transcription 
occurs. When reverse transcription and nuclear import are completed, the viral 
genome is integrated into the host’s genome. The provirus is transcribed, 
exported and translated to give rise to the viral proteins that assemble at the 
plasma membrane, to give rise to new virions that can bud from the cell. Many 
steps of the HIV-1 life cycle are targeted by antiviral factors such as TRIM5α, 
APOBEC3G, tetherin. HIV-1 has evolved strategies to counteract these 











SAMHD1 is a novel HIV-1 restriction factor in non-cycling myeloid cells and 
resting CD4+ T cells (4-6). In addition to HIV-1, SAMHD1 also blocks diverse 
retroviruses (7, 8). However, the mechanisms of SAMHD1-mediated retrovirus 
restriction and its physiological functions remain to be elucidated. 
 
1. Identification of SAMHD1 as an HIV-1 restriction factor 
 
Several studies have shown that while wild-type HIV-2 viruses grow well in 
human monocyte-derived DCs, growth of these Vpx-deletion mutants is 
completely suppressed, demonstrating that Vpx encoded by SIV and HIV-2 is 
essential for viral replication in cells of myeloid lineage (9, 10). Vpx is critical for 
HIV-2 infection in human macrophages by enhancing the efficiency of viral 
reverse transcription (10, 11). Further studies indicated that Vpx recruits a 
Cul4-DDB1-DCAF1 E3 ubiquitin ligase complex and induces proteasome-
degradation of an unknown restriction factor (11, 12). SAMHD1 was identified 
as a Vpx-interacting protein by mass spectrometry and turned out to be this 
putative HIV-1 restriction factor (4, 5). Knockdown of endogenous SAMHD1 in 
differentiated human monocytic THP-1 cells leads to accumulation of full-length 
HIV DNA. Conversely, overexpression of SAMHD1 in U937 cells inhibits HIV-1 







1.1 Structure and enzymatic activities of SAMHD1 
SAMHD1 is highly expressed in myeloid cells (4, 5) and was initially identified 
as the human ortholog of the mouse gene Mg11, which is induced by IFNγ 
treatment of macrophages and DCs (13). SAMHD1 expression is also induced 
in human macrophages following IFN-stimulatory DNA treatment in an IFN-
dependent fashion (14, 15). SAMHD1 protein consists of two domains; sterile 
alpha motif (SAM) domain and HD domain (Figure 2). SAM domains are 
protein-protein interaction motif and can also bind RNA (16). HD domains are 
characterized by a motif of doublet cation-coordinating His and Asp residues 
(H. . .HD. . .D) (17). The HD domains in proteins have putative nucleotidase 
and phosphodiesterase activities. Actually, it has been demonstrated that 
SAMHD1 is a dGTP-activated deoxynucleotide triphosphohydrolase (dNTPase) 
which cleaves deoxynucleoside triphosphates (dNTP) into their 
deoxynucleosides (dN) and inorganic triphosphates (18). dGTP-induced 
SAMHD1 tetramerization is required for dNTPase activity (19, 20). In addition 
to its triphosphohydrolase activity, SAMHD1 also has a metal-dependent 3ʹ-5ʹ 
exonuclease activity that degrades single-stranded RNA (ssRNA) or single-
stranded DNA (ssDNA) (21). Both enzymatic activities require the same active 



















Figure 2. Schematic illustration of SAMHD1 protein.  
SAMHD1 is a 626-amino acid protein that contatins an SAM and HD domain. 












SAMHD1 is a predominantly nuclear protein and the nuclear localization 
signal (NLS) of SAMHD1 protein has been identified to residues 11KRPR14 in 
the N-terminus of the protein (22, 23). But SAMHD1 is also found in the 
cytoplasm (6). Mutations in NLS of SAMHD1 changed its nuclear distribution to 
the cytoplasm. Cytosolic SAMHD1 can still restrict HIV-1 similar to the wild-
type protein. 
 
2. Mechanisms of SAMHD1-mediated retroviral restriction 
 
2.1 Inhibition retroviral reverse transcription by depleting intracellular 
dNTP pool. 
It was demonstrated that intracellular nucleotide levels can regulate retroviral 
infection efficiencies in cells (24). It has been also known that low levels of 
deoxynucleotides in peripheral blood lymphocytes could be a means to inhibit 
HIV-1 replication (25). Efficient HIV-1 infection in macrophages depends on the 
efficient cellular dNTP utilization by RT (26). Due to low cellular dNTP content 
in resting cells and non-cycling cells, HIV-1 entry into quiescent primary 
lymphocytes can initiate reverse transcription but cannot complete the full-
length HIV-1 cDNA synthesis (27). Recently, SAMHD1 was demonstrated to 







inorganic triphosphate in a deoxyguanosine triphosphate (dGTP)-dependent 
fashion. SAMHD1 reduces cellular dNTP concentrations below the levels 
required for retroviral reverse transcription (4, 5, 18, 28-30) (Figure 3). 
SAMHD1-mediated HIV-1 restriction in resting CD4+ T cells is also dependent 
on low dNTP levels in the cells (6). Furthermore, it was demonstrated that 
SAMHD1 restricts HIV-1 infection in monocyte-derived DCs by dNTP depletion 
since Vpx-mediated SAMHD1 degradation significantly increased intracellular 
dNTP concentrations (31). These studies indicate a strong correlation between 
low levels of cellular dNTPs and inhibition of HIV-1 replication. However, 
addition of dN into resting CD4+ T cells or macrophages to increase the 
intracellular dNTP pool cannot fully restore HIV-1 or SIV infections (6, 30), 
suggesting that decreasing dNTP pool by SAMHD1 may not be the sole 
mechanism underlying retroviral restriction in non-dividing cells. 
 
2.2 Phosphorylation of SAMHD1 negatively regulates its HIV-1 restriction 
ability. 
Two previous studies reported that phosphorylation of SAMHD1 at Thr 592 
impairs its HIV-1 restriction function (32, 33). However, mutagenesis studies 
indicated that T529 phosphorylation of SAMHD1 does not affect its dNTPase 





















Figure 3. Proposed mechanisms of SAMHD1-mediated HIV-1 restriction.  
SAMHD1 possesses two enzymatic activities. SAMHD1 functions as a 
dNTPase to decrease intracellular dNTP pool and thereby limits HIV-1 DNA 
synthesis during reverse transcription. Furthermore, SAMHD1 may directly 







and CDK1 is necessary for SAMHD1 phosphorylation. SAMHD1 
phosphorylation regulates ability of HIV-1 restriction, but not the cellular levels 
of dNTPs. Thus, SAMHD1-mediated HIV-1 inhibition may be independent of its 
dNTPase activity, suggesting additional cellular mechanisms may contribute to 
SAMHD1-mediated HIV-1 restriction function (Figure 4). One possibility is that 
phosphorylation of SAMHD1 may alter its structure or conformation and 
thereby regulate its HIV-1 restriction function. A second possibility is that 
phosphorylation of residue T592 controls the ability of SAMHD1 to interact with 
an unknown cofactor required for retroviral restriction. 
 
2.3 SAMHD1-mediated HIV-1 inhibition may involve its nuclease activity. 
In addition to the dNTPase activity of SAMHD1, recent studies suggest that 
SAMHD1 can bind to and degrade HIV-1 RNA, which can be a novel 
mechanism blocking retroviral infection (21, 34, 35). SAMHD1 was identified as 
a nucleic-acid-binding protein displaying a preference for RNA over DNA (34). 
It was demonstrated that ssRNA and ssDNA can promote the formation of the 
SAMHD1 complex (35). SAMHD1 associates with endogenous nucleic acids in 
situ. Using fluorescence cross-correlation spectroscopy, it was also shown that 
SAMHD1 specifically interacts with ssRNA and ssDNA. The formation of 



















Figure 4. Model for the regulation of SAMHD1 restriction activity by 
phosphorylation at the T592. 
SAMHD1 only exhibits antiretroviral activity when expressed in non-cycling 
cells because SAMHD1 is unphosphorylated in non-cycling cells. 









interaction with nucleic acids and complex formation requires the HD domain 
and the C-terminal region of SAMHD1, but not the SAM domain. Furthermore, 
mutations associated with AGS exhibit both impaired nucleic acid-binding and 
complex formation implicating that interaction with nucleic acids is an important 
function of SAMHD1 (35). These results highlight an important role of SAMHD1 
in nucleic acid metabolism. Notably, Beloglazova et al. have reported 
exonuclease activity of recombinant SAMHD1 protein (21). They found that 
purified full-length human SAMHD1 protein from E. coli possesses metal-
dependent 3ʹ-5ʹ exonuclease activity degrading ssRNA and ssDNA in vitro. 
SAMHD1 also exhibits strong binding to DNA and RNA with complex 
secondary structures. 
Together, these observations that there are the interactions between 
nucleic acids and SAMHD1 and SAMHD1 has exonuclease activity suggest 
that SAMHD1 may directly bind to and degrade retroviral genomic RNA in the 
infected cells (Figure 3). However, this hypothesis remains to be elucidated in 
HIV-1 infected cells. Further clarification of the mechanisms underlying 
SAMHD1-mediated HIV-1 RNA binding and degradation is important for fully 








3. SAMHD1 and Aicardi-Goutières syndrome 
 
Mutations in SAMHD1 gene are associated with Aicardi-Goutières syndrome 
(AGS) (14). AGS is a genetic autoimmune disorder that mimics congenital viral 
infection and is characterized by the aberrant production of type I interferon 
(IFN) (36). A disturbance of IFNα homeostasis is central to the pathogenesis of 
the prototypic autoimmune disorder systemic lupus erythematosus (SLE) (37-
39). In keeping with this, AGS clinically overlaps with SLE and some children 
with AGS develop an early-onset form of SLE (40-43). AGS can be caused by 
mutations in any of genes encoding TREX1 (AGS1) (44), 3′-5′ exonuclease 
with substrate preference for single-stranded DNA (ssDNA); the three 
components of the ribonuclease H2 (RNASEH2) endonuclease complex 
(AGS2, 3 and 4) (45), which cleaves the RNA moiety of RNA:DNA hybrids (46); 
adenosine deaminase acting on RNA 1 (ADAR1) (AGS6) (47), an RNA editing 
enzyme; MDA5 (AGS7, also known as IFIH1) (48), an innate sensor of viral 
RNA (49) (Figure 5).  
Trex1-/- mice spontaneously develop autoimmune multiorgan inflammation, 
which can be rescued by inactivation of the type I IFN system, demonstrating 
the critical pathogenic role of the IFN response (50-52). These findings led to a 























Figure 5. Genes identified to be associated with the AGS. 
Percentages of families with AGS with either biallelic or recognized dominant 
mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, 







resulting in intracellular accumulation of endogenous nucleic acids, which in 
turn trigger a type I IFN response (51) (Figure 6). Short ssDNA species derived 
from during DNA replication intermediates (53) or intermediates of endogenous 
retroelements (51) were proposed to be responsible for activation of the IFN 
system in Trex1-/- mice. Trex1 can also metabolize HIV reverse transcripts 
within infected cells (54), suggesting a key role in anti-retroviral defense and in 
clearance of nucleic acids derived from endogenous retroelements to avoid 
autoimmune disease. 
Loss of ADAR1 in mice is embryonically lethal and Adar1-/- mouse 
embryos, like Trex1-/- mice, display spontaneous production of type I IFN (55). 
ADAR1 catalyze the deamination of adenosine to inosine. Recently, A-to-I RNA 
editing inhibits antiviral inflammatory and IFN responses by altering RNA-
sensing innate immune signaling. Mice deficient for RNase H2 accumulate 
ribonucleotides in genomic DNA, resulting in a spontaneous DNA damage 
response (56, 57). 
Two recent studies reported the generation of samhd1-knockout mouse 
models (58, 59). Unlike the severe autoimmune disease in SAMHD1-deficient 
human patients with AGS, the samhd1-null mice were healthy beyond the age 
of 96 weeks. Spontaneous IFN production and significant induction of ISGs 







detectable amounts of circulating IFN proteins or upregulation of ISG products 
in their sera. These observations suggest that SAMHD1 deficiency in mice is 
not sufficient to enhance the production or release of type I IFNs and mouse 
SAMHD1 function might be redundant or not directly involved in the innate 
immune responses to nucleic acids in mice. Further studies are needed to 












































Figure 6. Model of AGS pathogenesis. 
Lack of TREX1 activity results in accumulation of ssDNA thereby augmenting 
the pool of nucleic acids in the cytoplasm. ssDNA is recognized by cGMP-AMP 
synthase (cGAS), DNA sensor. Unmodified self-RNAs due to lack of function 
mutations are sensed by RIG-I and MDA5. RNASEH2 and SAMHD1 would 
also impair the control of nucleic acid homeostasis and activate type I IFN 





























1. Ethics statement 
 
Adult blood samples were anonymously provided by the Blood Center of the 
Korean Red Cross, Seoul, under the approval of the Institutional Review Board 
of Korean Red Cross with consent for research use. Written informed consent 
was obtained from the blood donors with the approval of the Ethics Committee 
of the Korean Red Cross. Experiments involving human blood were approved 





Full-length human SAMHD1 was amplified by PCR from cDNA generated by 
the reverse transcription of RNA from HeLa cells, and the PCR product was 
inserted into a pGEX-4T-1 vector and a pMSCV-puro vector. The SAMHD1D207N, 
SAMHD1D311A, SAMHD1D137N and SAMHD1Q548A mutants were generated using 
the nPfu-forte DNA Polymerase Kit (Enzynomics). Retroviral vectors encoding 
the wild-type or T592 phosphorylation variants SAMHD1 were described 








3. Protein expression and purification 
 
The GST-tagged, full-length, human SAMHD1 proteins (GST-SAMHD1) were 
expressed in E. coli Rosetta (λDE3) (Novagen). The Rosetta cells were grown 
in Terrific broth containing ampicillin (100 μg/ml) at 37 °C to an optical density 
(OD) 600 of 2.0, and the cells were rapidly cooled on ice to 16 °C. After 
induction with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG; Ducheba), 
the cells were allowed to grow for 16 h at 16 °C. The E. coli pellet containing 
the GST fusion protein was lysed with PBS, and the protein was purified using 
glutathione-Sepharose column chromatography, as previously described (61). 
 
4. Preparation of DNA and RNA substrates 
 
Fragments of the HIV-1 5ʹ LTR, gag, and 3ʹ LTR were transcribed in vitro using 
T7 RNA polymerase (Enzynomics). The transcripts were purified using 
denaturing polyacrylamide gel electrophoresis (PAGE; 5% polyacrylamide/8 M 
urea). Synthetic DNA and RNA oligonucleotides were 5ʹ-end labeled with 32P 
using T4 polynucleotide kinase and [γ-32P]ATP. The nucleotides were 
precipitated by the addition of 3 M ammonium acetate and 100% (vol/vol) 
ethanol. The nucleotides pellets were washed with 75% ethanol, dried and 







dsDNAs and dsRNAs (Table 1) were prepared by annealing the 
oligonucleotides. 
 
5. In vitro nuclease assay 
 
Assays were performed in 20-μl reaction mixtures containing PBS 
supplemented with 5 mM MgCl2, 2 mM DTT, 10% glycerol, 0.01% NP-40, 32P-
labeled nucleic acid substrates, and purified recombinant proteins (150 nM) or 
immunoprecipitated proteins at 37 °C for the indicated times. The reactions 
were stopped by the addition of an equal volume of formamide loading buffer 
and then boiled. The products were separated in 15% polyacrylamide gels 
containing 8 M urea and buffered with 0.5 × Tris-borate-EDTA (TBE) and then 
analyzed by autoradiography using a phosphorimager (BAS2500, Fujifilm). 
 
6. dGTP-triphosphohydrolase assay 
 
An enzymatic assay based on thin layer chromatography was performed as 
described previously (28). The purified recombinant protein was incubated in 
50 mM Tris-HCl (pH 8.0), 20 mM KCl, 5 mM MgCl2, 0.1 μCi [α-32P]dGTP, and 
200 μM cold dGTP for 3 h at 37 °C. The reactions were stopped by heat-







dGMP, dGDP, and dGTP standards onto polyethyleneimine (PEI)-cellulose 
plates (Sigma-Aldrich) and subsequently separated using a mobile phase of 
1.2 M LiCl. After separation, the α-32P-labeled reaction products were 
visualized using a phosphorimager, and the migration indicators were detected 
by UV-C (254 nm). 
 
7. Cells and reagents 
 
U937 and THP-1 cells were cultured in RPMI 1640 supplemented with 10% 
fetal bovine serum (Hyclone), 2 mM GlutaMAX-I, 100 U/ml penicillin, and 100 
μg/ml streptomycin (Invitrogen). HEK293T cells and Phoenix Ampho cells were 
cultured in DMEM supplemented as described for RPMI 1640. Stable U937 
cells expressing SAMHD1 proteins were obtained by retroviral infection. The 
pMSCV-puro construct was used to transfect Phoenix Ampho cells using the 
calcium phosphate method. Two days later, the retrovirus-containing 
supernatant was used to transduce U937 cells by spin infection with 8 μg/ml 
polybrene. The transduced cells were selected in 1 μg/ml puromycin. 
Peripheral blood mononuclear cells (PBMCs) were obtained from human blood 
by density gradient centrifugation using Ficoll-Paque Plus™ (Amersham 







based positive selection kit (IMagTM) and anti-human CD14 beads (BD 
Biosciences). This procedure routinely yielded over 90% pure CD14+ cells, as 
verified by flow cytometry. Monocyte-derived macrophages (MDMs) were 
obtained from monocytes by culturing the cells for 3 days with GM-CSF (10 
ng/ml) and M-CSF (20 ng/ml). CD4+ T cells were isolated from the PBMCs 
using a magnetic bead-based positive selection kit (IMagTM) and anti-human 
CD4 beads (BD Biosciences). T cells were activated, and post-activation 
resting T cells were obtained as previously described (6). Resting CD4+ T cells 
(2 × 106 cells/ml) were treated overnight with PHA-L (2 mg/ml). The next day, 
the medium was exchanged and cells were incubated in RPMI medium with 20 
IU/ml IL-2 for 3 days. Activated CD4+ T cells were electroporated with 
SAMHD1-specific siRNA or non-specific siRNAs. The siRNA-treated cells were 
cultivated in RPMI medium with gradually reducing concentrations of IL-2. The 
activation state of CD4+ T cells was analyzed by monitoring the surface 
expression of the activation markers CD25 and CD69. The experimental 
design for the time course analysis of MDMs and CD4+ T cells is shown in 










8. RNA interference 
 
siRNA targeting SAMHD1 was purchased from Dharmacon. MDMs and CD4+ T 
cells (2×106 cells) were electroporated in 100-µL reactions with siRNA (10 nM) 
using the Neon Transfection System (Invitrogen). Transfections with ON-
TARGETplus Non-targeting pool (Dharmacon) were performed in parallel as a 
negative control. The MDMs and CD4+ T cells were pulsed once each for 20 
ms at 2150 and 2100 volts, respectively. 
 
9. Viruses and VLP production 
 
HEK293T cells were transfected with 10 μg of HIV-1-GFP, HIV-1D443N-GFP or 
pLaiΔenvGFP3 and 2 μg of HCMV-VSV-G using the calcium phosphate 
method. Vpx-containing and control VLPs were generated by the transfection 
of HEK293T cells with pSIV3+ or pSIV3+ Δvpx. Culture supernatants were 
collected and filtered (0.45 μm) 48 h after transfection. U937 cells (0.5×106 
cells/ml) were seeded in 12-well plates and differentiated for 20 h in PMA 
(phorbol-12-myristate-13-acetate, 30 ng/ml). The cells were infected with 100 
ng of pseudotyped viruses for 2 h. The cells were then washed and cultured for 








10. Quantitative real-time PCR 
 
VSV-G-pseudotyped HIV-1-GFP-infected cells were harvested at various time 
points, and DNA was isolated using the QIAamp Blood DNA Minikit (Qiagen). 
qPCR was performed with the iCycler iQ real-time PCR detection system 
(BioRad) using HIV-1-specific primers: R/U5 (forward, GCCTCAATAAA 
GCTTGCCTTGA; reverse, TGACTAAAAGGGTCTGAGGGATCT) and U5/ψ 
(forward, TGTGTGCCCGTCTGTTGTGT; reverse, GAGTCCTGCGTCGAGAG 
ATC). RNA isolation from HIV-1-GFP-infected cells or SAMHD1-silenced THP-
1 cells was performed at various time points according to the manufacturer’s 
instructions (Invitrogen). One microgram of RNA was treated with DNase I prior 
to qPCR analysis and isolated by phenol:chloroform extraction. The data were 
normalized to an internal control gene, MDM2 or β-actin. The purified RNA was 
reverse transcribed using random primers, and real-time PCR was performed 
with the iCycler iQ real-time PCR detection system (BioRad) using HIV-1-













Table 1. Synthetic nucleic acids used in nuclease assays. 
Oligomer Sequence 
20-bp ssRNA 5ʹ-CUCCAUCACCCUCCAUCACC-3ʹ 









































Table 2. HIV-1 specific primers used in qRT-PCR analysis. 
Primers Sequences 
Primer 1 Forward (R/U5) 5ʹ-GCCTCAATAAAGCTTGCCTTGA-3ʹ 
Primer 1 Reverse (R/U5) 5ʹ-TGACTAAAAGGGTCTGAGGGATCT-3ʹ 
Primer 2 Forward 5ʹ-GTAGTGTGTGCCCGTCTGTT-3ʹ 
Primer 2 Reverse 5ʹ-TTTCAAGTCCCTGTTCGGGC-3ʹ 
Primer 3 Forward 5ʹ-AGAGCGTCGGTATTAAGCGG-3ʹ 
Primer 3 Reverse 5ʹ-TGCGAATCGTTCTAGCTCCC-3ʹ 
Primer 4 Forward 5ʹ-CTAGAACGATTCGCAGTTAATCCT-3ʹ 
Primer 4 Reverse 5ʹ-CTATCCTTTGATGCACACAATAGAG-3ʹ 
Primer 5 Forward (gag) 5ʹ-ACTCTAAGAGCCGAGCAAGC-3ʹ 
Primer 5 Reverse (gag) 5ʹ-TCTAGTGTCGCTCCTGGTCC-3ʹ 
Primer 6 Forward 5ʹ-CTGTTGAGGTGGGGATTTACCA-3ʹ 
Primer 6 Reverse 5ʹ-CTGTCCTTTTCTGGCAGCACT-3ʹ 
Primer 7 Forward 5ʹ-CCTGGATTCCTGAGTGGGAG-3ʹ 
Primer 7 Reverse 5ʹ-TAGTTTCCCTATTGGCTGCCC-3ʹ 
Primer 8 Forward 5ʹ-GTCAGCTAAAAGGGGAAGCCA-3ʹ 
Primer 8 Reverse 5ʹ-CCACTGGCTACATGAACTGCT-3ʹ 
Primer 9 Forward 5ʹ-GAAAGGACCAGCAAAGCTCC-3ʹ 
Primer 9 Reverse 5ʹ-CACCTGCCATCTGTTTTCCAT-3ʹ 
Primer 10 Forward 5ʹ-TGGAAGCATCCAGGAAGTCAG-3ʹ 
Primer 10 Reverse 5ʹ-CCGCTTCTTCCTGCCATAGG-3ʹ 
Primer 11 Forward (egfp) 5ʹ-CAACAGCCACAACGTCTATATCATG-3ʹ 
Primer 11 Reverse (egfp) 5ʹ-ATGTTGTGGCGGATCTTGAAG-3ʹ 
Primer 12 Forward 5ʹ-GCTACAAGGGACTTTCCGCT-3ʹ 
Primer 12 Reverse 5ʹ-AGAGAGACCCAGTACAGGCA-3ʹ 
Primer 12 Forward 5ʹ-GCTACAAGGGACTTTCCGCT-3ʹ 








11. RNA-Seq analysis 
 
Total RNA was extracted from mock- and SAMHD1-expressing U937 cells 
uninfected or infected with HIV-1 using TRIzol reagent (Invitrogen) by 
manufacturer's instruction followed by addition of spike-in poly(A)-tailed RNA 
(GeneChip Eukaryotic Poly-A RNA control Kit, Affymetrix). After ribosomal RNA 
depletion using Epicentre's Ribo-Zero™ Kits, RNA was fragmented using RNA 
fragmentation reagent (Ambion). After dephosphorylation by Antarctic 
phosphatase (NEB), 5' end of fragmented and dephosphorylated RNA was 
phospho-labeled using [γ-32P]ATP and T4 polynucleotide kinase (TaKaRa). 35-
60 nucleotide RNA was extracted in a polyacrylamide, 7 M urea, TBE gel. 3' 
adaptor (5′/rApp/TGGAATTCTCGGGTGCCAAGG/ddC/-3′, IDT) was ligated 
using T4 RNA ligase truncated K227Q (NEB) followed by ligation of 5' adaptor 
(5′ Solexa linker, 100-M; 5′-rGrUrUrCrArGrArGrUrUrCrUrArCrArGrUrCrCrGrA 
rCrGrA rUrC-3′, IDT) using T4 RNA ligase (TaKaRa). The 5' and 3' adaptor-
ligated RNA was reverse transcribed using RNA RT Primer (RTP; 5′-GCCTTG 
GCACCCGAGAATTCCA-3′, IDT) and SuperScript™ III reverse transcriptase 
(Invitrogen). Each sample was amplified by PCR using Phusion polymerase 
(Thermo Scientific), 5′ end Illumina RNA PCR Primer (RP1) and 3′ end Illumina 







single-end sequencing in an Illumina HiSeq2500 sequencer. Illumina standard 
pipeline and software-CASAVA were employed for processing of raw imaging, 
base calling and generating FASTQ sequence reads. Before aligning reads to 
the reference sequences, I filtered low quality reads, adapter-containing 
sequences, and artifact reads using in house software and FASTX-Toolkit 
(FASTQ/A short-reads pre-processing tools, hannonlab.cshl.edu/fastx toolkit). 
The read sequences were then aligned to the UCSC hg19 human reference 
genome and HIV-1 NL4-3 genome using bowtie2-2.1.037. The abundance of 
transcripts was measured as the score of RPKM (Reads Per Kilobase of exon 
model per Million mapped reads). I applied spike-in normalization to all 12 
samples to reduce variations across samples. 
 
12. RNA immunoprecipitation (RIP) 
 
The RNA immunoprecipitation protocol (62) was adapted to analyze the 
interactions between SAMHD1 and HIV-1-GFP genomic RNA. HIV-1-GFP-
infected cells were cross-linked by 1% formaldehyde for 10 min at room 
temperature. The crosslinking reaction was stopped by addition of glycine (1 M, 
pH 7.0) to a final concentration of 0.25 M followed by incubation at room 







resuspended in RIPA buffer (50 mM Tris-HCl, pH 7.4/1% NP40/0.5% sodium 
deoxycholate/0.05% SDS/1 mM EDTA/150 mM NaCl) containing protease 
inhibitors and an RNase inhibitor. The cell suspension was sonicated and 
centrifuged for 10 min at 9000 × g, and the resulting supernatant was pre-
cleared by incubation with protein G-agarose beads. The pre-cleared 
supernatant was incubated with anti-HA or anti-Flag antibody-conjugated 
beads for 2 h at 4 °C. The beads were washed with RIPA buffer and 
resuspended with reversal buffer (50 mM Tris-HCl, pH 7.0/5 mM EDTA/10 mM 
DTT/1% SDS) followed by an incubation for 45 min at 70 °C to reverse the 
crosslinks. The immunoprecipitated RNAs were isolated according to the 
manufacturer’s protocol (Invitrogen). 
 
13. Northern blot analysis 
 
Approximately one microgram of total RNA was analyzed on a 15% 
polyacrylamide gel containing 7 M urea after ethidium bromide staining. For 
Northern blot analysis, an oligomer probe specific for tRNALys3 (5ʹ-TGGCGCCC 
GAACAGGGAC-3ʹ) (63) was used, which was complementary to 18 
nucleotides at the 3ʹ end of tRNALys3. The RNA in the gel was transferred onto 







RNA was then cross-linked to the nylon membrane using EDC (1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide), and the membrane was baked in an oven 
at 80 °C overnight. Pre-hybridization and hybridization were subsequently 
carried out in the presence of 32P-5ʹ-labeled nucleotide probes at 42 °C for 24 h. 
Following hybridization, the membrane was washed five times in 2x SSC (three 
times in 2x SSC containing 0.05% SDS and twice in 2x SSC containing 0.1% 
SDS) before autoradiography. 
 
14. Cell fractionation 
 
For nuclear-cytoplasmic fractionation, monocytes and MDMs were washed in 
cold PBS and resuspended with lysis buffer (10 mM HEPES, pH 7.9/0.1 mM 
EDTA/2 mM MgCl2/0.1 mM EGTA/10 mM KCl/0.1 mM DTT/0.5 mM PMSF). 
NP-40 was added to obtain a final concentration of 1% and mixed by gentle 
inversion. The cytoplasmic extracts were separated from intact nuclei by low-
speed centrifugation at 4 °C and 1400 ×g for 30 sec. The nuclear pellet was 
resuspended in buffer (20 mM HEPES, pH 7.9/0.1 mM EDTA/0.1 mM 
EGTA/0.4 M NaCl/1 mM DTT/1 mM PMSF). The nuclear and cytoplasmic 






















1. SAMHD1 is a processive 3ʹ-5ʹ exonuclease. 
SAMHD1 is a myeloid cell-specific HIV-1 restriction factor that is counteracted 
by Vpx (4, 5). SAMHD1 possesses a dGTP-dependent dNTPase activity (18, 
29), and studies have proposed that SAMHD1 blocks HIV-1 infection by 
depleting the intracellular dNTP pool (6, 28, 31). Contrary to the proposed role 
for dNTPase activity in SAMHD1-mediated restriction of HIV-1, recent studies 
have shown that the phosphorylation of SAMHD1 regulates the ability of this 
enzyme to restrict HIV-1 infection but does not alter the cellular dNTP levels 
(32, 33, 64). In addition, SAMHD1 is a nucleic acid binding protein (7, 34, 35) 
and exhibits a processive exonuclease activity in vitro against a broad 
spectrum of substrates, such as single-stranded DNAs and RNAs as well as 
the RNA in RNA:DNA hybrids (21). Although the physiological relevance of 
SAMHD1 nuclease activity remains unknown, SAMHD1 might bind to HIV-1 
RNA and degrade this RNA or reverse transcription intermediates. 
In contrast to Beloglazova et al.(21), other studies have not observed 
SAMHD1 nuclease activity (18, 29, 34); therefore, I tested whether SAMHD1 
possesses nuclease activity. I incubated purified, full-length, wild-type human 
SAMHD1 (SAMHD1WT) with various types of 20- or 30-mer nucleic acid 








































Figure 7. SAMHD1 is a ssRNA-specific ribonuclease. 
(A) Purified GST-SAMHD1 (150 nM) was incubated for 30 min at 37°C with 
various synthetic nucleic acid substrates (20-mers) that were 5ʹ-end labeled 
with [γ-32P]ATP (indicated by an asterisk). The products were analyzed by 
electrophoresis and autoradiography. RNA and DNA are represented by red 
and blue lines, respectively. (B) GST-SAMHD1 was assayed for ribonuclease 
activity in time course experiments. The ribonuclease activity was determined 
using a 20-mer ssRNA as substrate by measuring and quantifying the 
disappearance of the substrate. (C) An RNase activity assay performed as 











stranded RNAs (ssRNA), releasing 5'-mononucleotides and leaving a short 
undigested 5~8-mer core. To characterize the ribonuclease function of 
SAMHD1 more precisely, SAMHD1 was incubated for different periods of time 
with a 20-mer ssRNA. This incubation resulted in the loss of the substrate and 
in the accumulation of 5~8-mer final products with a direct substrate/product 
relationship. The specific activity of SAMHD1 was 58.5±0.81 pmol∙min-1∙nmol-1 
(Figure 7B). This value is comparable with that reported for eukaryotic 
exoribonuclease RNase R (65). No fragments of intermediate length were 
observed (Figure 7B and C), which is a distinct feature of a processive rather 
than a distributive mode of hydrolysis. 
No nuclease activity was detected on dsRNA, ssDNA, dsDNA, and RNA-
DNA hybrid substrates, whereas these substrates were digested by positive 
control nucleases (Figure 8). Essentially identical results were obtained when 
the experiments were repeated using the 40-mer nucleic acid substrates 
described by Beloglazova et al. (21) (Figure 9). A previous study (21) observed 
that SAMHD1 degrades ssRNA, ssDNA, RNA in RNA:DNA hybrids, and the in 
vitro-transcribed HIV-1 RNA fragments; however, I observed that only ssRNAs, 
including in vitro-HIV-1 transcripts in the size range of 336 to 593 nucleotides 
(Figure 10), were sensitive to SAMHD1 digestion. These discrepancies might 


































Figure 8. Nuclease activity of SAMHD1 compared to other enzymes. 
Various types of 20-mer nucleic acid substrates were incubated with GST-
SAMHD1 (150 nM) and analyzed for nuclease activity of SAMHD1, as in 
Figure 7. RNase A, DNase I and RNase H were used as positive nuclease 









































Figure 9. Nuclease activity of SAMHD1 with 40-nt nucleic acid substrates. 
Various types of 40-mer nucleic acid substrates (50 nM) with 5' or 3' overhangs 
or blunt ends were 5ʹ-end labeled with [γ-32P]ATP and incubated with purified 
GST-SAMHD1 (150 nM) for 15 and 30 min at 37 °C. The products were 








































Figure 10. SAMHD1 cleaves in vitro-transcribed HIV-1 RNAs. 
In vitro transcripts of HIV-1 5ʹ LTR (336 bases), gag (517 bases), and 3ʹ LTR 
(593 bases) RNAs were synthesized using a T7 RNA polymerase transcription 
kit. These RNA substrates (0.2 μM) were incubated with GST-SAMHD1 (0.4, 1, 
and 2 μM) at 37 °C for 1 h. The reaction products were analyzed by 













however, my results are consistent with the observation of Beloglazova et al. 
(21) that SAMHD1 cleaves ssRNAs processively in vitro.  
Next, to determine the direction of the degradation of ssRNA, SAMHD1 
was incubated with another 30-mer ssRNA labeled with 32P at its 3ʹ-end instead 
of its 5ʹ -end. This incubation led to the loss of the signal, with no intermediate, 
and the signal of one nucleotide size was increased (Figure 11A). By contrast, 
the substrate with a phosphate group at its 3ʹ-end was not degraded (Figure 
11B). These results show that the SAMHD1-mediated degradation of ssRNA 
occurs in the 3ʹ to 5ʹ direction and displays a strong preference for a 3ʹ-end 
containing a free hydroxyl group. The degradation of ssRNA by SAMHD1 
required Mg2+ (Figure 12) and correlated with the presence of the SAMHD1WT 
protein across chromatographic fractions (Figure 13). Considering the 
preferential binding of SAMHD1 to ssRNA compared with ssDNA (34, 35) and 
the absence of an interaction between endogenous SAMHD1 and dsRNA, 






































Figure 11. SAMHD1 degrades RNA with a preference for a 3ʹ-end 
containing a free hydroxyl group in a 3ʹ to 5ʹ direction. 
GST-SAMHD1 was assayed for exoribonuclease activity in time course 
experiments. The RNA substrates were labeled with 32P at 3ʹ-end. The 3ʹ-end 
of the 30-mer substrate carried a hydroxyl group (A) or a phosphate group (B). 









































Figure 12. Metal specificity of SAMHD1. 
5ʹ-end 32P-labeled ssRNA (20-mer) was incubated with GST-SAMHD1 (150 nM) 
without added metal or with 5 mM Mg2+, Mn2+, Zn2+, or Ca2+. The reaction 







































Figure 13. Correlation of the presence of the SAMHD1WT protein with 
RNase activity. 
Recombinant GST-tagged SAMHD1 was expressed in E. coli Rosetta cells and 
purified using glutathione-Sepharose column chromatography. The resulting 
eluate was further purified by a size-exclusion column (YMC-Pack Diol-200). 
(A) HPLC chromatograms of the resulting eluate and BSA molecular weight 
standards (dotted line, Mr≈66 kD). Inset, UV spectrum of the peak at 19.8 min 
corresponding to reduced co-eluted glutathione. (B) 10 fractions corresponding 
to peaks I, II, and III were collected, stained with Coomassie Blue and assayed 










2. Ribonuclease and dNTPase are dual and separate 
functions of SAMHD1. 
 
The dNTPase function of SAMHD1 is allosterically activated by dGTP. 
Mutations of Asp 137 and Arg 145 in the allosteric site or Asp 207 and Asp 311 
in the catalytic site in the HD domain abolish dNTPase activity entirely (18, 29). 
Unlike dNTPase activity, RNase activity does not require the cofactor dGTP 
(Figure 7); therefore, I proposed that these two catalytic functions of SAMHD1 
might be physically separable. I characterized AGS-associated SAMHD1 
mutations and mutations near the allosteric dGTP-binding sites for defects in 
RNase or dNTPase activity and identified several point mutations that caused 
loss of function. Mutations at amino acids 207 and 311 in the catalytic site 
abolished both RNase and dNTPase activities (Figure 14). A mutation at 
residue D137 in the allosteric site (SAMHD1D137N) had no effect on the RNase 
activity but did abolish the dNTPase activity (Figure 14), whereas the AGS-
mutant SAMHD1Q548A showed the opposite phenotype. Due to the relative 
insolubility of GST-SAMHD1Q548A proteins in E. coli, we used SAMHD1Q548A 
proteins immunoprecipitated from U937 monocytic cells. Unlike the processive 
degradation seen in SAMHD1WT and SAMHD1D137N, the Q548A mutation 

































Figure 14. Identification of amino acid residues required for RNase 
activity or dNTPase activity of SAMHD1. 
(A) Recombinant GST-fusion SAMHD1 was expressed in E. coli Rosetta cells 
and purified using glutathione-Sepharose column chromatography. 
Approximately 1 μg of indicated proteins were subjected to 10% SDS-PAGE, 
and the gel was stained with Coomassie Blue. The molecular weight standards 
(lane 1) are indicated. (B) An RNase activity assay performed for SAMHD1 
mutants as described in Figure 7 using 20-mer ssRNA substrates. (C) A dGTP-












accumulation of intermediate-size fragments (16–19 nucleotides) (Figure 15). 
Considering that a shift from a processive to distributive degradation often 
occurs under the conditions that decrease the affinity of an exonuclease for its 
substrates (66, 67), this switch in mode may be because of a lowered affinity of 
SAMHD1Q548A for ssRNA. Indeed, recent studies have shown that 
SAMHD1Q548A exhibits impaired ssRNA binding (21, 35). Notably, dGTP 
inhibited the RNase activity of SAMHD1 on ssRNA substrates, and this 
inhibition correlated with a shift from a processive to a distributive mode of 
action (Figure 16), suggesting that dGTP interferes with the binding of 












































Figure 15. Q548 residue of SAMHD1 is important for RNase activity not 
for dNTPase activity. 
The HA-tagged SAMHD1WT and SAMHD1Q548A proteins were purified from the 
PMA-differentiated U937 cells using anti-HA antibody. An RNase and a dGTP 
triphosphohydrolase assays were performed as described in Figure 14. IP, 








































Figure 16. dGTP inhibits the RNase activity of SAMHD1. 
5ʹ-end 32P-labeled ssRNA (20-mer) was incubated with GST-SAMHD1 (150 nM) 
in the presence of dGTP (1, 5, 10 mM) at 37 °C for 30 min. GST-SAMHD1 was 
preincubated with dGTP for tetramerization. Reaction products were analyzed 













3. The ribonuclease function of SAMHD1 is critical for 
HIV-1 restriction. 
 
The identification of the SAMHD1D137N and SAMHD1Q548A mutants that 
retain only one of two enzymatic activities enabled me to determine the 
discrete contribution of SAMHD1 RNase activity to HIV-1 restriction. For this 
analysis, I stably expressed wild-type SAMHD1 or each of the SAMHD1 
mutants in U937 human pro-monocytic cells, which do not express 
endogenous SAMHD1 and can be differentiated to macrophage-like cells by 
PMA treatment to enable them support HIV-1 replication (4, 28, 32, 33). The 
wild-type and mutant proteins were expressed at comparable levels (Figure. 
15A). Consistent with in vitro data (Figure 14), the catalytic mutants 
(SAMHD1D207N and SAMHD1D311A) and the allosteric mutant (SAMHD1D137N) did 
not reduce the intracellular levels of dNTPs, whereas SAMHD1Q548A decreased 
the cellular levels of dNTPs (Figure 17B). SAMHD1WT effectively inhibited HIV-
1 infection, whereas the catalytically defective SAMHD1D207N and SAMHD1D311A 
proteins did not restrict HIV-1 infection. Notably, SAMHD1D137N restricted HIV-1 
infection to nearly the same extent as SAMHD1WT. SAMHD1Q548A was unable 
to block HIV-1 restriction despite its ability to decrease the cellular levels of 



































Figure 17. The intracellular dNTP pools were measured in U937 cells 
stably expressing SAMHD1 variants. 
(A) Expression level of SAMHD1 variants in U937 cells. U937 cell lines stably 
expressing SAMHD1 variants were generated by using retroviral vector. Cells 
were treated with PMA (30 ng/ml) for 20 h and lysed. The cell extracts were 
immunoblotted to verify the expression of SAMHD1. GAPDH serves as a 
loading control. (B) Quantification of dNTPs from U937 cell lines stably 
expressing SAMHD1 variants. The data are presented as the mean ± s.d. of 
triplicate independent experiments. (* indicates significant differences 
compared with the mock-transfected control at P < 0.05 using the two-tailed 







































Figure 18. The RNase but not the dNTPase function of SAMHD1 is 
required for HIV-1 restriction. 
U937 cells stably expressing SAMHD1 mutants were treated with PMA and 
infected by pLaiΔenvGFP3, a HIV-1-GFP reporter virus with the LAI backbone. 
After 48 h, the percentages of GFP-positive cells were analyzed using flow 
cytometry. The percentage of GFP-positive cells was calculated relative to the 
number of GFP-positive mock-transfected cells. The data are presented as the 
mean ± s.d. of triplicate independent experiments. (* and ** indicate significant 
differences compared with the mock-transfected control at P < 0.05 and P < 











function of SAMHD1 is essential for HIV-1 restriction. The quantification of viral 
cDNA intermediates by quantitative PCR using primers specific to different 
stages of HIV-1 reverse transcription showed that SAMHD1D137N inhibited the 
synthesis of both the early and late viral cDNA products at a level comparable 
to SAMHD1WT (Figure 19), indicating that SAMHD1 RNase functions at the 


















































Figure 19. SAMHD1 RNase functions at the early step of HIV-1 reverse 
transcription. 
The synthesis of viral cDNA intermediates was determined 24 h after infection 
by qPCR using the R/U5 (early products) and U5/ψ (late products) primers. 
Isolated RNAs were treated with DNase I to remove the potential DNA 
contaminants prior to qPCR analysis and the data were normalized to an 
internal control gene (MDM2). The data are presented as the mean ± s.d. of 
triplicate independent experiments. (** indicates significant differences 
compared with the mock-transfected control at P < 0.001 using the two-tailed 











4. SAMHD1 associates with and induces destabilization 
of the HIV-1 genomic RNA. 
 
I studied the mechanism by which SAMHD1 RNase activity inhibits HIV-1 
replication. HIV-1 reverse transcription involves two RNA components: the 
tRNALys3 primer and the HIV-1 genomic RNA, which is a template for cDNA 
synthesis. The experimental design is outlined in Figure 20A. Total cellular 
RNA was isolated from U937 cells infected with HIV-1-GFP at the early time 
points post-infection. Northern blot analysis revealed that SAMHD1 had no 
effect on tRNALys3 levels (Figure 20B). I tested whether SAMHD1 RNase 
activity affects HIV-1 RNA levels. The quantification of viral RNA content by 
quantitative reverse transcription-PCR (qRT-PCR) showed that HIV-1 genomic 
RNA was significantly reduced in cells expressing SAMHD1WT or SAMHD1D137N 
at 3 and 6 h post-infection (h.p.i) (Figure 21), but SAMHD1D207N, SAMHD1D311A, 
and SAMHD1Q548A did not reduce the level of HIV-1 genomic RNA; these 
results were consistent with FACS analyses (Figure 18). At 1 h.p.i, both 
SAMHD1WT and SAMHD1D137N had no impact on the viral RNA content (Figure 
21) most likely because the HIV-1 genomic RNA is inaccessible to SAMHD1 at 
this early time. To exclude primer-specificity bias, 12 pairs of primers spanning 


































Figure 20. SAMHD1 had no effect on tRNALys3 levels. 
(A) The experimental design for time course analysis. SAMHD1-expressing 
U937 cells were infected with HIV-1-GFP and total cellular RNA was extracted 
at different time points post-infection. (B) Northern blot analysis of tRNALys3 
levels using 18-mer nucleotide probe specific for tRNALys3 as a probe. Equal 











































Figure 21. The level of HIV-1 genomic RNA was decrease in SAMHD1-
expressing cells during infection. 
The total cellular RNA was extracted from SAMHD1-expressing, HIV-1-GFP-
infected U937 cells. The HIV-1 RNA content was quantified by qRT-PCR using 
HIV-1 gag-specific primers. The data were normalized to an internal β-actin. (* 
and ** indicate significant differences compared with the mock-transfected 













HIV-1-infected cells. At 3 and 6 h.p.i, the HIV-1 genomic RNA level in 
SAMHD1WT-expressing cells was distinctly lower compared with the mock-
transfected control cells (Figure 22). During reverse transcription, the RNase H 
activity of the viral RT degrades the HIV-1 genomic RNA. To exclude the effect 
of the viral RT RNase H activity on the HIV-1 genomic RNA level, I used RNase 
H-defective HIV-1 (HIV-1D443N) in which the amino acid Asp 443 of RT was 
mutated to Asn (D443N) (68). The level of HIV-1D443N RNA was lower in 
SAMHD1WT-expressing cells compared with mock-transfected cells (Figure 23), 
indicating that SAMHD1 can degrade HIV-1 RNA in the absence of reverse 
transcription. 
RNA-Seq analysis also confirmed the degradation of HIV-1 genomic RNA 
by SAMHD1. Total RNA was extracted 0, 1, and 3 h.p.i from mock or mutant 
SAMHD1-expressing U937 cells uninfected or infected with HIV-1. I applied a 
spike-in normalization for all 12 samples to reduce background noise and allow 
comparison between samples. At 3 h.p.i, the relative read count of HIV-1 
genomic RNA in SAMHD1WT and SAMHD1D137N-expressing cells was lower 
than that in mock-transfected or SAMHD1D207N-expressing cells despite the 
considerable reduction of HIV-1 genomic RNA levels in all cell types compared 
with the levels observed at 1 h.p.i (Figure 24A and B). The relative tRNALys3-
































Figure 22. SAMHD1 degrades multiple regions of the HIV-1 genomic RNA 
during infection. 
(A) HIV-1 genomic amplification sites of the qRT-PCR primers used in (B), (C), 
and (D). (B-D) U937 cells stably expressing empty vector or wild-type (WT) 
SAMHD1 protein were infected with HIV-1-GFP, and total cellular RNA was 
extracted at 1 (B), 3 (C), and 6 h.p.i (D). The HIV-1 genomic RNA levels were 
analyzed by qRT-PCR using site-specific primers corresponding to multiple 
regions, as indicated in (A). The data were normalized to the GAPDH mRNA 
levels and compared with the relative level in mock-transfected U937 cells. The 







































Figure 23. SAMHD1 can degrade HIV-1 RNA in the absence of reverse 
transcription. 
To exclude the effect of the viral RT RNase H activity on the HIV-1 genomic 
RNA level, RNase H-defective HIV-1 (HIV-1D443N) were used. The level of HIV-
1D443N RNA was lower in SAMHD1WT-expressing cells compared with mock-
transfected cells. (* indicates significant differences compared with the mock-






































Figure 24. RNA-Seq analysis of HIV-1 degradation by SAMHD1 after 
infection. 
(A) Relative HIV-1 genome abundance in reads per kilobase per million 
mapped reads (RPKM) calculated from RNA-Seq data. (B) Coverage of the 
RNA-Seq data across the HIV-1 genome in U937 cells expressing SAMHD1WT, 
SAMHD1D207N and SAMHD1D137N after HIV-1-GFP infection. A schematic 
diagram of the viral gene loci in the HIV-1 genome is shown below the 
coverage plots. (C) Relative quantity of tRNALys3 based on the reads that 
mapped non-redundantly to the tRNALys3 loci, expressed as percentiles of the 











mediated knockdown of SAMHD1 or Vpx-mediated degradation of endogenous 
SAMHD1 in THP-1 cells also caused an approximately four-fold increase in the 
HIV-1 genomic RNA level (Figure 25). To verify that SAMHD1 targets HIV-1 
genomic RNA for degradation, I used RNA immunoprecipitation (RIP) assays 
(62) to test whether SAMHD1 associated with HIV-1 genomic RNA during 
infection. A significant enrichment of HIV-1 RNA was observed in the 
immunoprecipitates from cells expressing SAMHD1WT-HA. The HIV-1 RNA 
enrichment was more pronounced for the SAMHD1D207N-HA catalytic mutant 
with an approximately eight-fold increase (Figure 26), suggesting that 
SAMHD1 associates with HIV-1 genomic RNA. In contrast, interaction of 
SAMHD1Q548A-HA with HIV-1 RNA was markedly reduced when compared with 
the SAMHD1WT-HA, supporting that impaired binding of SAMHD1Q548A-HA to 
HIV-1 RNA accounts for its inability to cleave short ssRNA and HIV-1 RNA 
(Figure 15). 
Next, I analyzed the role of SAMHD1 RNase in regulating HIV-1 RNA 
stability in primary human monocyte-derived macrophages (MDMs) and CD4+ 
T cells. Cell surface expression of MDM-differentiation markers (CD71, CD80, 
and CD86) was increased 3 days after treatment with M-CSF and GM-CSF 
(Figure 27). The activation state of CD4+ T cells was analyzed by monitoring 

































Figure 25. HIV-1 RNA was stabilized when SAMHD1 was depleted. 
shRNA-mediated silencing of SAMHD1 (A) or Vpx-mediated degradation of 
SAMHD1 (B) in THP-1 cells increases HIV-1 RNA stability. THP-1 cells 
expressing shRNAs, Vpx or negative control were treated with PMA for 24 h 
followed by infection with HIV-1-GFP. The total viral RNA was quantified by 
qRT-PCR at the indicated times post-infection. Knockdown efficiency was 
determined by immunoblot analysis. (* and ** indicate significant differences 
compared with shControl or –Vpx VLP control at P < 0.05 and P < 0.001, 






































Figure 26. Enrichment of HIV-1 genomic RNA in the SAMHD1 
immunoprecipitates. 
U937 cells containing the empty vector (mock) and vectors encoding 
SAMHD1WT-HA, SAMHD1D207N-HA, or SAMHD1Q548A-HA were infected for 90 
min with HIV-1-GFP. SAMHD1 was immunoprecipitated using anti-HA 
antibodies. The purified RNAs in the immunoprecipitates were quantified by 
qRT-PCR using HIV-1 gag-specific primers. (** indicates significant differences 
compared with the mock-transfected control at P < 0.001 using the two-tailed 







































Figure 27. Differentiation of monocytes into MDMs. 
The experimental design for time course analysis is shown. CD14+ monocytes 
derived from three donors were treated with M-CSF and GM-CSF and 
differentiated to MDMs for 3 days. The differentiation state of monocytes was 
analyzed by monitoring the surface expression of the markers (CD71, CD80, 








































Figure 28. Activation of CD4+ T cells. 
The experimental design for time course analysis is shown. The PBMC-derived 
CD4+ T cells from three donors were activated, and post-activation resting 
CD4+ T cells were obtained as previously described. Expression of CD4 was 
analyzed by flow cytometry using FITC-conjugated anti-CD4 antibody. The 
activation state of CD4+ T cells was analyzed by monitoring the surface 












and 10 (Figure 28). SAMHD1 silencing in MDMs markedly reduced the cellular 
SAMHD1 levels (Figure 29A) and rendered MDMs more permissive to HIV-1 
infection (Figure 29B and 31A), a result that is correlated with the increased 
stability of HIV-1 RNA. The enhancement of HIV-1 RNA stability ranged from 
approximately two to four-fold, depending on the donor (Figure 29). Similar to 
the results obtained using MDMs, SAMHD1 silencing in resting CD4+ T cells 
increased the infectivity of HIV-1 (Figure 30B and 31B). In these cells, 
increased HIV-1 RNA stability was observed 3 h.p.i (Figure 30C). The 
degradation of SAMHD1 by Vpx could also stabilize the viral RNAs of HIV-1 
and HIV-1D443N in resting CD4+ T cells (Figure 32). These results show that 
similar to the U937 monocytic cells, the antiviral activity of SAMHD1 is 
correlated with its RNase activity in primary human MDMs and resting CD4+ T 
cells. Biochemical fractionation revealed that SAMHD1 is localized in both the 
cytoplasm and nucleus of MDMs and monocytes (Figure 33), which is 
consistent with previous observations (6, 34). Considering that cytoplasmic 
SAMHD1 can block HIV-1 infection (69, 70), these data suggest that after virus 
uncoating, SAMHD1 associates with and degrades HIV-1 RNA in the 


































Figure 29. SAMHD1 degrades HIV-1 genomic RNA in primary human 
MDMs. 
CD14+ monocytes isolated from three donors were differentiated into MDMs. 
MDMs were transfected with siRNA to SAMHD1 or control siRNA and then 
infected with 100 ng of HIV-1-GFP. (A) The efficiency of SAMHD1 knockdown 
was evaluated by qRT-PCR. (B) Quantification of GFP-positive cells by flow 
cytometry of MDMs. (C) Total viral RNA was quantified at the indicated times 
post-infection by qRT-PCR using gfp-specific primers. The data were 
normalized to an internal control gene (β-actin). (* and ** indicate significant 
differences compared with siControl at P < 0.05 and P < 0.001, respectively, 





































Figure 30. SAMHD1 degrades HIV-1 genomic RNA in primary human CD4+ 
T cells. 
Post-activated resting CD4+ T cells from three donors were transfected with 
siRNA to SAMHD1 or control siRNA and then infected with 100 ng of HIV-1-
GFP. (A) The efficiency of SAMHD1 knockdown was evaluated by qRT-PCR. 
(B) Quantification of GFP-positive cells by flow cytometry of MDMs. (C) Total 
viral RNA was quantified at the indicated times post-infection by qRT-PCR 
using gfp-specific primers. The data were normalized to an internal control 
gene (β-actin). (* indicates significant differences compared with siControl at P 







































Figure 31. Knockdown of SAMHD1 in MDMs and resting CD4+ T cells 
increases HIV-1-GFP infectivity. 
MDMs (A) and CD4+ T cells (B) were transfected with siRNA to SAMHD1 or 
control siRNA and then 100 ng of HIV-1-GFP. Flow cytometric analysis 48 h.p.i 






































Figure 32. Effect of Vpx treatment on the HIV-1 RNA stability in resting 
CD4+ T cells. 
Resting CD4+ T cells were challenged with HIV-1-GFP (A) or HIV-1-GFPD443N 
(B) in the presence of Vpx VLP. Total viral RNA was quantified at the indicated 
times post-infection by qRT-PCR using gfp-specific primers. The data were 
normalized to an internal control gene (β-actin). Knockdown efficiency was 
determined by immunoblot analysis. (* indicates significant differences 







































Figure 33. Cellular distribution of SAMHD1 in both the cytoplasm and 
nucleus. 
Nuclear and cytoplasmic fractions were prepared from MDMs or monocytes 
and analyzed by immunoblotting with anti-SAMHD1 antibody. Tubulin and 













5. Phosphorylation of SAMHD1 regulates RNase activity. 
 
The phosphorylation of SAMHD1 at T592 causes the loss of HIV-1 
restriction without decreasing cellular dNTP levels (32, 33, 64). I tested 
whether the phosphorylation of SAMHD1 affects its RNase activity in HIV-1 
restriction. In PMA-treated U937 cells where SAMHD1WT is not phosphorylated 
on residue T592 (32, 33), SAMHD1WT blocked HIV-1 infection. In contrast, 
SAMHD1T592D containing the phosphomimetic D residue was unable to inhibit 
HIV-1 infection (Figure 34), confirming previous results (32). Notably, the 
stability of HIV-1 genomic RNA was enhanced by three to four-fold in cells 
expressing SAMHD1T592D compared with cells expressing SAMHD1WT (Figure 
35). In contrast to this in vivo observation, the recombinant SAMHD1T592D 
protein was as effective as the SAMHD1WT and the nonphosphorable 
SAMHD1T592V in degrading ssRNA substrates in vitro (Figure 36). 
Phosphorylation did not appears to influence the structural conformation (19), 
oligomerization and dNTPase activity (32), or in vitro RNase activity of the 
enzyme. RIP analysis revealed that SAMHD1WT and SAMHD1T592D bound to 
HIV-1 genomic RNA with similar affinities, indicating that phosphorylation of 
SAMHD1 T592 does not interfere with substrate binding (Figure 37). Therefore, 







the phosphorylation of SAMHD1 might promote the recruitment of cellular 
factors that negatively regulate its RNase activity in vivo. Alternatively, 
SAMHD1 phosphorylation might interfere with the interaction of SAMHD1 with 
unidentified cofactors. My results reveal that the phosphorylation of SAMHD1 
at T592 is a mechanism that negatively regulates its RNase activity and 















































Figure 34. The role of SAMHD1 in the regulation of HIV-1 restriction by 
phosphorylation T592. 
U937 cells stably expressing an empty vector (mock) or Flag-tagged SAMHD1 
variants were treated with PMA and infected with 100 ng of pLaiΔenvGFP3. (A) 
Flow cytometric analysis 48 h.p.i to measure the percentage of GFP-positive 
cells. (B) The percentage of GFP-positive cells was calculated relative to the 
number of GFP-positive mock-transfected cells. (C) Immunoblot analysis of cell 






































Figure 35. SAMHD1 phosphorylated on residue T592 is unable to degrade 
HIV-1 RNA. 
U937 cells stably expressing an empty vector (mock), Flag-tagged SAMHD1WT 
or SAMHD1T592D were treated with PMA and infected with 100 ng of HIV-1-GFP. 
The HIV-1 RNA content was quantified by qRT-PCR using HIV-1 gag-specific 
primers. The data were normalized to an internal β-actin. (** indicates 
significant differences compared with the mock-transfected control at P < 0.001 







































Figure 36. The RNase activity of SAMHD1T592D is not affected. 
Recombinant SAMHD1T592V and SAMHD1T592D proteins were purified from E. 
coli. Purified proteins were incubated for 30 min at 37°C with various synthetic 
nucleic acid substrates (20-mers) that were 5ʹ-end labeled with [γ-32P]ATP. The 








































Figure 37. Effect of SAMHD1 T592 phosphorylation on substrate binding. 
U937 cells expressing vector alone, SAMHD1WT or SAMHD1T592D were infected 
for 90 min with HIV-1-GFP and crosslinked by formaldehyde. Cell lysates were 
immunoprecipitated with anti-Flag antibody. Purified RNAs from the 
















I identify SAMHD1 as a phospho-regulated RNase that blocks HIV-1 infection 
through a direct cleavage of HIV-1 genomic RNA. Several observations are 
consistent with the model that SAMHD1-mediated HIV-1 restriction occurs 
through the action of the RNase but not the dNTPase activity of SAMHD1 
(Figure 38). First, the dNTPase-negative and RNase-positive SAMHD1D137N 
mutant is able to block HIV-1 replication, whereas the dNTPase-positive and 
RNase-negative SAMHD1Q548A mutant with a phenotype opposite to the 
SAMHD1D137N mutant is defective in restricting HIV-1 infection. Second, the 
phosphorylation of SAMHD1 modulates the ability of this enzyme to restrict 
HIV-1 infection but does not affect its ability to alter cellular dNTP levels (32, 33, 
64), and the RNase function of SAMHD1 in HIV-1 restriction is regulated by 
phosphorylation. Third, the role of dNTPase activity in HIV-1 restriction was 
consistent with the observation that exogenous deoxynucleosides (dNs; 
precursors of dNTPs) can alleviate SAMHD1-mediated restriction (28). 
However, in macrophages and resting CD4+ T cells with low dNTP levels (71), 
the Vpx-mediated degradation of SAMHD1 is significantly more effective than 
the addition of exogenous dNs in overcoming HIV-1 restriction (6, 28), 






















Figure 38. HIV-1 restriction mechanism of SAMHD1. 
Once HIV-1 genomic RNA is released from the core in the cytoplasm, 
SAMHD1 recognizes and directly degrades the HIV-1 genomic RNA, therefore 







The partial alleviation of SAMHD1-mediated HIV-1 restriction by the 
addition of exogenous dNs might be an indirect consequence of impaired RNA 
substrate binding and/or RNase activity of SAMHD1 caused by the increase in 
dGTP levels. The crystal structure of SAMHD1 catalytic core (aa. 120-626) 
reveals that this protein is dimeric and indicates a structural basis for the 
allosteric activation of catalytic activity against dNTPs by dGTP binding (18). In 
contrast, functional and structural analyses have demonstrated that SAMHD1 
oligomerizes in a dGTP-dependent manner up to a tetramer and that the 
tetramerization of SAMHD1 is required for its dNTPase and anti-HIV-1 
activities (19, 20). Notably, Yan et al. (20) observed that SAMHD1 with a 
mutation at the allosteric dGTP-binding site D137 did not undergo 
oligomerization and was mostly monomeric in the presence of dGTP. The 
mutation at D137 (SAMHD1D137N) abolishes SAMHD1 dNTPase but not RNase 
activity (Figure 14), indicating that unlike the dNTPase activity, the 
tetramerization of SAMHD1 is not necessary for its RNase activity. Based on 
previous data as well as the results of my research, I propose that SAMHD1 is 
a dual-function enzyme exhibiting several mutually exclusive and predominant 
activities that depend on the dGTP pool, which is normally the smallest 
component of the total dNTP pool and is most affected by SAMHD1 







that harbor active RNase but not dNTPase activity, enabling HIV-1 restriction 
through the cleavage of HIV-1 RNA. At high dGTP levels, SAMHD1 
tetramerizes, yielding an enzyme with an inactive RNase but active dNTPase 
function, although there is no direct evidence for the correlation of dGTP-
induced SAMHD1 tetramerization and the inactivation of RNase catalytic 
activity in vivo (Figure 39). An alternative but not mutually exclusive possibility 
is that the ssRNA and dNTP substrates might compete with each other for a 
common active site on the enzyme. Notably, dGTP is both a substrate and an 
activator of the SAMHD1 dNTPase function (18, 29). This model is consistent 
with several observations from previous studies: high levels of dGTP impair the 
binding of SAMHD1 to nucleic acid substrates in vitro (21, 32), the switch from 
a processive to distributive mode of ssRNA degradation in a dGTP-dependent 
manner (Figure 16) is indicative of competitive inhibition of ssRNA-binding by 
dGTP, and that the mutations in the D207 and D311 amino acids at the 
enzymatic catalytic site abolish both RNase and dNTPase activities (Figure 14). 
These two hypotheses may provide an explanation for why SAMHD1 blocks 
HIV-1 infection only in non-cycling cells with low dNTP levels, such as DCs and 
macrophages (4), but not in cycling cells with high dNTP levels (6, 32, 73). 
Another explanation might be that dNTP limitation in non-cycling cells, would 




















Figure 39. Regulation model of SAMHD1-dual enzymatic activities. 
Tetramerization of SAMHD1 is required for its dNTPase activity in a dGTP-
dependent manner. Conversely, the RNase activity of SAMHD1 does not 
depend on either dGTP binding or tetramer formation. It is possible that that 








for the action of SAMHD1 RNase against HIV-1 RNA. Considering that 
uncontrolled and high dNTP concentrations are mutagenic for genome 
replication (74) and that dNTP destruction by SAMHD1 contributes to control of 
the dNTP concentration in proliferating cells (72), SAMHD1 dNTPase most 
likely has a more general role in regulating the dNTP pool by 'positive 
regulation' in which the accumulated dGTPs activate the SAMHD1 dNTPase 
activity, thereby preventing the overproduction of dNTPs. 
It is unknown whether the anti-viral activity of SAMHD1 is specific to 
retroviruses, although SAMHD1 is known to restrict the infections caused by a 
diverse range of retroviruses (7, 8). Furthermore, it is unclear how retroviral 
RNAs are selectively targeted for degradation over various cellular RNAs. 
SAMHD1 RNase activity exhibits no apparent sequence specificity (Figure 7, 9 
and 10). Exoribonucleases like SAMHD1 digest a diverse range of substrates 
from poly(A) to highly structured RNAs such as tRNA and rRNA. In some 
cases, exoribonuclease can act alone to process the substrate, but in most 
cases, a helicase or other cofactor is required to direct the RNA into the active 
site of the enzyme (75). 
I can speculate that SAMHD1 specifically recognizes retroviral RNA-
associated structural elements unique to retroviruses, such as RT or the 







render cellular RNAs insensitive to SAMHD1. A variety of cis-elements or 
trans-acting regulatory factors, such as RNA-binding proteins, protect cellular 
RNAs from eukaryotic RNases (76). Therefore, the absence of these 
regulatory factors in retroviral genomes might result in the specific 
susceptibility of viral RNAs to degradation by SAMHD1. 
Similar to mutations in SAMHD1, mutations in the genes encoding TREX1 
and RNASEH2 cause AGS (44, 45). The exonuclease TREX1 digests excess 
cytosolic HIV-1 DNA that would otherwise trigger an innate immune response 
(54), and the endonuclease RNASEH2 degrades the RNA moiety of RNA:DNA 
hybrids (45, 46). The identification of SAMHD1 as an RNase suggests that 
similar to TREX1 and RNASEH2, SAMHD1 has a critical role in nucleic acid 
metabolism related to the prevention of an innate immune response; therefore, 
my results provide an insight into the mechanisms underlying HIV-1 restriction 
and the pathogenesis of AGS. 
Based on my data and the links between the accumulation of nucleic acids 
and the inappropriate triggering of innate immune responses (36), the natural 
function of SAMHD1 is likely to clean up dysfunctional cellular RNAs or RNA 
species derived from endogenous retroelement, thus preventing an unwanted 
inflammatory response (Figure 40). Human endogenous retroviruses make up 





















Figure 40. Model of AGS pathogenesis in deficiency of SAMHD1. 
Lack of function mutations in SAMHD1 would impair the control of nucleic acid 
homeostasis. Accumulation RNA debris or RNA species derived from 
retroelements activats type I IFN pathway through unknown sensors. The 
aberrant activation of innate immune response could cause pro-inflammatory 








autoimmune diseases (77). In line with the specific recognition of HIV-1 RNA 
by SAMHD1 and the ability of SAMHD1 to restrict a wide range of retroviruses 
(7), the byproducts of human endogenous retroviruses are potentially major 
targets of SAMHD1. In addition, this mechanism may also explain the 
molecular basis of AGS and related lupus-like diseases in patients with loss-of-
function mutations in SAMHD1 (14). The failure to degrade endogenous RNA 
debris is likely a principle pathway causing the aberrant activation of innate 
immune responses in individuals with SAMHD1-mediated autoimmune 
diseases. In fact, my observations reveal the direct association of SAMHD1 
with RNA species in human cell lines. This unique property of SAMHD1 which 
affects the balance between HIV-1 infection and innate immune response 
could be exploited to develop a new class of intervention strategies for 
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국 문 초 록 
AGS는 유전적인 질병으로 환자에게서 핵산매개면역반응에 의한 자가
면역질환 증상이 나타난다. AGS와 관련된 돌연변이 유전자 중에는 
SAMHD1이 있다. SAMHD1은 HIV-1 억제인자로 작용하여 세포분열이 일어
나지 않는 대식세포, 수지상 세포, 휴지상태의 CD4+ T 세포에서 HIV-1의 역
전사 과정을 방해한다. SAMHD1은 dNTP를 분해하는 효소 활성을 가지고 
있으며 dGTP가 다른 자리 조절자로써 dNTPase 효소 활성을 갖도록 한다. 
따라서 SAMHD1은 세포내 dNTP의 양을 줄임으로써 HIV-1의 복제를 저해
한다고 연구되었다. 그러나 최근 보고에 따르면, SAMHD1의 dNTPase 활성
과 관계없이 SAMHD1 단백질 인산화 여부에 따라 HIV-1의 복제를 억제하
는 능력이 조절되는데, 이는 SAMHD1의 또 다른 역할이 있음을 시사한다. 
본 연구에서는 SAMHD1이 RNA 분해효소 기능을 가지고 있음을 밝혔으며 
이 효소 기능이 HIV-1을 억제하는데 필수적임을 보였다. AGS 질병과 관련
된 SAMHD1의 돌연변이와 dGTP가 결합하지 못하는 돌연변이 SAMHD1을 
이용하여 2가지 효소 작용 중에 어떤 것이 HIV-1 억제에 중요한지에 대해
서 확인하였다. RNA 분해효소 활성만 가지고 있는 SAMHD1D137N의 경우는 
HIV-1를 억제할 수 있었으나 dNTPase 활성만 가지는 SAMHD1Q548A는 HIV-







억제 기작의 핵심이라는 것을 의미한다. 실제 SAMHD1은 HIV-1 감염초기에 
직접 HIV-1 유전체 RNA에 결합하여 분해함으로써 HIV-1 생활사에 타격을 
입히는 것으로 확인되었다. 인간의 대식세포나 CD4+ T 세포에 SAMHD1의 
발현을 감소시켰을 때, HIV-1 유전체 RNA가 안정화 되는 실험적 결과를 이
를 뒷받침한다. 또한 592번째 아미노산인 트레오닌의 인산화에 의한 HIV-1
의 억제 기능 조절은 SAMHD1의 HIV-1 유전체 RNA 분해 작용에 대한 조
절로 이루어짐을 보였다. 여러 실험 결과들을 통해 나는 SAMHD1이 가지는 
두 가지 효소 활성 중에서 dNTPase가 아닌 RNase 효소 활성이 HIV-1를 
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